Skip to content
Clinical Trials – home

Waldemar Placek DERM-ART Szkoleniowo.Naukowy i Naukowo-Badawczy Ośrodek

Research site

Poland ul. Batalionów Chłopskich 24, 81-415 Gdynia, Poland

  • Psoriasis
  • Adult patients

About Specializations

Waldemar Placek DERM-ART Szkoleniowo.Naukowy i Naukowo-Badawczy Ośrodek in Gdynia, Poland specialises in clinical trials of conditions such as Psoriasis, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

The Waldemar Placek DERM-ART Szkoleniowo.Naukowy i Naukowo-Badawczy Ośrodek conducts research in skin and connective tissue diseases, concentrating on moderate to severe plaque psoriasis. Current studies aim to test the effectiveness of emerging therapies and to monitor their long‑term safety for patients.

  • Assess the efficacy of a new biologic agent compared with placebo
  • Evaluate long‑term safety and tolerability of the investigational treatment
  • Examine the therapeutic impact of an oral compound over a 16‑week period

Located in Gdynia, Poland, this non‑commercial health‑care site manages three clinical trials with a single investigator, contributing valuable data to the field of psoriasis research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. Batalionów Chłopskich 2481-415 GdyniaPoland
Recruiting now
no trials
Conditions studied
1

More sites in GdyniaPoland

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

3 clinical trials

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.